Study identifier:D1444C00004
ClinicalTrials.gov identifier:NCT00228462
EudraCT identifier:2004-002833-38
CTIS identifier:N/A
A 1-year, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (abbreviated)
schizophrenia
Phase 3
No
Seroquel (quetiapine)
All
197
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jun 2025 by AstraZeneca
AstraZeneca
-
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.
Location
Location
Bydgoszcz, Poland
Location
Sofia, Bulgaria
Location
Tuszyn, Poland
Location
Radnevo, Bulgaria
Location
Burgas, Bulgaria
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.